ID   KPCD1_HUMAN             Reviewed;         912 AA.
AC   Q15139; A6NL64; B2RAF6;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   14-OCT-2008, sequence version 2.
DT   05-OCT-2010, entry version 107.
DE   RecName: Full=Serine/threonine-protein kinase D1;
DE            EC=2.7.11.13;
DE   AltName: Full=Protein kinase C mu type;
DE   AltName: Full=Protein kinase D;
DE   AltName: Full=nPKC-D1;
DE   AltName: Full=nPKC-mu;
GN   Name=PRKD1; Synonyms=PKD, PKD1, PRKCM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   MEDLINE=94164979; PubMed=8119958;
RA   Johannes F.-J., Prestle J., Eis S., Oberhagemann P., Pfizenmaier K.;
RT   "PKCmu is a novel, atypical member of the protein kinase C family.";
RL   J. Biol. Chem. 269:6140-6148(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=22459283; PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S.,
RA   Sun H., Du H., Pepin K., Artiguenave F., Robert C., Cruaud C.,
RA   Bruels T., Jaillon O., Friedlander L., Samson G., Brottier P.,
RA   Cure S., Segurens B., Aniere F., Samain S., Crespeau H., Abbasi N.,
RA   Aiach N., Boscus D., Dickhoff R., Dors M., Dubois I., Friedman C.,
RA   Gouyvenoux M., James R., Madan A., Mairey-Estrada B., Mangenot S.,
RA   Martins N., Menard M., Oztas S., Ratcliffe A., Shaffer T., Trask B.,
RA   Vacherie B., Bellemere C., Belser C., Besnard-Gonnet M.,
RA   Bartol-Mavel D., Boutard M., Briez-Silla S., Combette S.,
RA   Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., Muselet D.,
RA   Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., Trybou A.,
RA   Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L.,
RA   Verdier J., Verdier-Discala C., Hillier L.W., Fulton L., McPherson J.,
RA   Matsuda F., Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W.,
RA   Quetier F., Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   INTERACTION WITH ADAP1.
RX   MEDLINE=22774667; PubMed=12893243; DOI=10.1016/S0006-291X(03)01187-2;
RA   Zemlickova E., Dubois T., Kerai P., Clokie S., Cronshaw A.D.,
RA   Wakefield R.I.D., Johannes F.-J., Aitken A.;
RT   "Centaurin-alpha(1) associates with and is phosphorylated by isoforms
RT   of protein kinase C.";
RL   Biochem. Biophys. Res. Commun. 307:459-465(2003).
RN   [6]
RP   FUNCTION, ENZYME REGULATION, PHOSPHORYLATION AT TYR-432; TYR-463 AND
RP   TYR-502, AND MUTAGENESIS OF TYR-432; TYR-463; TYR-502 AND LYS-612.
RX   PubMed=12637538; DOI=10.1074/jbc.M213224200;
RA   Storz P., Doppler H., Johannes F.J., Toker A.;
RT   "Tyrosine phosphorylation of protein kinase D in the pleckstrin
RT   homology domain leads to activation.";
RL   J. Biol. Chem. 278:17969-17976(2003).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205 AND THR-210, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Prostate cancer;
RX   PubMed=17487921; DOI=10.1002/elps.200600782;
RA   Giorgianni F., Zhao Y., Desiderio D.M., Beranova-Giorgianni S.;
RT   "Toward a global characterization of the phosphoproteome in prostate
RT   cancer cells: identification of phosphoproteins in the LNCaP cell
RT   line.";
RL   Electrophoresis 28:2027-2034(2007).
RN   [8]
RP   PHOSPHORYLATION AT TYR-95.
RX   PubMed=17804414; DOI=10.1074/jbc.M703584200;
RA   Doppler H., Storz P.;
RT   "A novel tyrosine phosphorylation site in protein kinase D contributes
RT   to oxidative stress-mediated activation.";
RL   J. Biol. Chem. 282:31873-31881(2007).
RN   [9]
RP   ENZYME REGULATION, PHORBOL-ESTER BINDING, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF PRO-157 AND PRO-281.
RX   PubMed=18076381; DOI=10.1042/BJ20071334;
RA   Chen J., Deng F., Li J., Wang Q.J.;
RT   "Selective binding of phorbol esters and diacylglycerol by individual
RT   C1 domains of the PKD family.";
RL   Biochem. J. 411:333-342(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-742, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-217; SER-237; SER-397;
RP   SER-401 AND SER-910, AND MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205; SER-208; THR-217;
RP   SER-235; SER-247; SER-249; SER-345; SER-379; THR-395; SER-397;
RP   SER-399; THR-400; SER-401; SER-420; SER-448; SER-460; SER-473;
RP   SER-548; SER-549; SER-742; SER-888; SER-890 AND SER-910, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   VARIANTS [LARGE SCALE ANALYSIS] TYR-152 AND LYS-857.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] PRO-225; GLN-478; SER-585; MET-677;
RP   LEU-679 AND ARG-891.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Converts transient diacylglycerol (DAG) signals into
CC       prolonged physiological effects, downstream of PKC. Involved in
CC       resistance to oxidative stress through activation of NF-kappa-B.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Magnesium.
CC   -!- ENZYME REGULATION: Activated by DAG and phorbol esters. Phorbol-
CC       ester/DAG-type domain 1 binds DAG with high affinity and appears
CC       to play the dominant role in mediating translocation to the cell
CC       membrane and trans-Golgi network. Phorbol-ester/DAG-type domain 2
CC       binds phorbol ester with higher affinity. Autophosphorylation of
CC       Ser-742 and phosphorylation of Ser-738 by PKC relieves auto-
CC       inhibition by the PH domain. Phosphorylation on Tyr-463 by the
CC       Src/Abl pathway in response to oxidative stress, is also required
CC       for activation.
CC   -!- SUBUNIT: Interacts (via N-terminus) with ADAP1/CENTA1. Interacts
CC       with Src.
CC   -!- INTERACTION:
CC       P12830:CDH1; NbExp=3; IntAct=EBI-1181072, EBI-727477;
CC       O15264:MAPK13; NbExp=2; IntAct=EBI-1181072, EBI-2116951;
CC       P02795:MT2A; NbExp=4; IntAct=EBI-1181072, EBI-996616;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Membrane. Note=Translocation to
CC       the cell membrane is required for kinase activation.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. PKD subfamily.
CC   -!- SIMILARITY: Contains 1 PH domain.
CC   -!- SIMILARITY: Contains 2 phorbol-ester/DAG-type zinc fingers.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PRKCMID41860ch14q11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X75756; CAA53384.1; -; mRNA.
DR   EMBL; AK314170; BAG36853.1; -; mRNA.
DR   EMBL; AL135858; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471078; EAW65971.1; -; Genomic_DNA.
DR   IPI; IPI00782950; -.
DR   PIR; A53215; A53215.
DR   RefSeq; NP_002733.2; -.
DR   UniGene; Hs.508999; -.
DR   ProteinModelPortal; Q15139; -.
DR   SMR; Q15139; 140-197, 244-324, 586-847.
DR   DIP; DIP-38481N; -.
DR   IntAct; Q15139; 23.
DR   STRING; Q15139; -.
DR   PhosphoSite; Q15139; -.
DR   PRIDE; Q15139; -.
DR   Ensembl; ENST00000331968; ENSP00000333568; ENSG00000184304.
DR   GeneID; 5587; -.
DR   KEGG; hsa:5587; -.
DR   CTD; 5587; -.
DR   GeneCards; GC14M030045; -.
DR   H-InvDB; HIX0037727; -.
DR   HGNC; HGNC:9407; PRKD1.
DR   HPA; CAB018367; -.
DR   HPA; HPA029834; -.
DR   MIM; 605435; gene.
DR   PharmGKB; PA33771; -.
DR   eggNOG; prNOG16370; -.
DR   HOVERGEN; HBG003564; -.
DR   InParanoid; Q15139; -.
DR   OMA; LQDSSGD; -.
DR   OrthoDB; EOG9FXTT2; -.
DR   PhylomeDB; Q15139; -.
DR   BRENDA; 2.7.11.13; 247.
DR   Pathway_Interaction_DB; igf1_pathway; IGF1 pathway.
DR   Pathway_Interaction_DB; lysophospholipid_pathway; LPA receptor mediated events.
DR   Reactome; REACT_22258; Metabolism of lipids and lipoproteins.
DR   NextBio; 21670; -.
DR   ArrayExpress; Q15139; -.
DR   Bgee; Q15139; -.
DR   CleanEx; HS_PKD1; -.
DR   CleanEx; HS_PRKD1; -.
DR   Genevestigator; Q15139; -.
DR   GermOnline; ENSG00000184304; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0004697; F:protein kinase C activity; IEA:EC.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR011993; PH_type.
DR   InterPro; IPR001849; Pleckstrin_homology.
DR   InterPro; IPR002219; Prot_Kinase_C-like_PE/DAG-bd.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR015727; Protein_Kinase_C_mu-related.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   Gene3D; G3DSA:2.30.29.30; PH_type; 1.
DR   PANTHER; PTHR22968; PKC_mu_like; 1.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   ATP-binding; Complete proteome; Cytoplasm; Kinase; Magnesium;
KW   Membrane; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Repeat; Serine/threonine-protein kinase; Transferase;
KW   Zinc; Zinc-finger.
FT   CHAIN         1    912       Serine/threonine-protein kinase D1.
FT                                /FTId=PRO_0000055714.
FT   DOMAIN      422    541       PH.
FT   DOMAIN      583    839       Protein kinase.
FT   ZN_FING     146    196       Phorbol-ester/DAG-type 1.
FT   ZN_FING     270    320       Phorbol-ester/DAG-type 2.
FT   NP_BIND     589    597       ATP (By similarity).
FT   COMPBIAS     17     26       Poly-Ala.
FT   COMPBIAS    200    203       Poly-Arg.
FT   ACT_SITE    706    706       Proton acceptor (By similarity).
FT   BINDING     612    612       ATP.
FT   MOD_RES      95     95       Phosphotyrosine.
FT   MOD_RES     205    205       Phosphoserine.
FT   MOD_RES     208    208       Phosphoserine.
FT   MOD_RES     210    210       Phosphothreonine.
FT   MOD_RES     217    217       Phosphothreonine.
FT   MOD_RES     235    235       Phosphoserine.
FT   MOD_RES     237    237       Phosphoserine.
FT   MOD_RES     247    247       Phosphoserine.
FT   MOD_RES     249    249       Phosphoserine.
FT   MOD_RES     345    345       Phosphoserine.
FT   MOD_RES     379    379       Phosphoserine.
FT   MOD_RES     395    395       Phosphothreonine.
FT   MOD_RES     397    397       Phosphoserine.
FT   MOD_RES     399    399       Phosphoserine.
FT   MOD_RES     400    400       Phosphothreonine.
FT   MOD_RES     401    401       Phosphoserine.
FT   MOD_RES     420    420       Phosphoserine.
FT   MOD_RES     432    432       Phosphotyrosine.
FT   MOD_RES     448    448       Phosphoserine.
FT   MOD_RES     460    460       Phosphoserine.
FT   MOD_RES     463    463       Phosphotyrosine.
FT   MOD_RES     473    473       Phosphoserine.
FT   MOD_RES     502    502       Phosphotyrosine.
FT   MOD_RES     548    548       Phosphoserine.
FT   MOD_RES     549    549       Phosphoserine.
FT   MOD_RES     738    738       Phosphoserine; by PKC (By similarity).
FT   MOD_RES     742    742       Phosphoserine; by autocatalysis.
FT   MOD_RES     888    888       Phosphoserine.
FT   MOD_RES     890    890       Phosphoserine.
FT   MOD_RES     910    910       Phosphoserine; by autocatalysis (By
FT                                similarity).
FT   VARIANT     152    152       H -> Y (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_035468.
FT   VARIANT     225    225       S -> P.
FT                                /FTId=VAR_042324.
FT   VARIANT     478    478       K -> Q (in dbSNP:rs55852813).
FT                                /FTId=VAR_042325.
FT   VARIANT     585    585       P -> S (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_042326.
FT   VARIANT     677    677       R -> M (in a lung bronchoalveolar
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_042327.
FT   VARIANT     679    679       P -> L (in dbSNP:rs34588699).
FT                                /FTId=VAR_042328.
FT   VARIANT     825    825       R -> K (in dbSNP:rs11161065).
FT                                /FTId=VAR_046988.
FT   VARIANT     857    857       E -> K (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_035469.
FT   VARIANT     891    891       H -> R (in dbSNP:rs45582934).
FT                                /FTId=VAR_042329.
FT   MUTAGEN     157    157       P->G: Increase in ability to bind phorbol
FT                                ester, loss of ability to bind DAG.
FT   MUTAGEN     281    281       P->G: No effect on ability to bind
FT                                phorbol ester, slight increase in ability
FT                                to bind DAG.
FT   MUTAGEN     432    432       Y->E: Decreased phosphorylation level
FT                                when coexpressed with SRC in HeLa cells.
FT                                Unchanged phosphorylation level when
FT                                coexpressed with ABL.
FT   MUTAGEN     432    432       Y->F: Decreased phosphorylation level
FT                                when coexpressed with SRC in HeLa cells.
FT                                Unchanged phosphorylation level when
FT                                coexpressed with ABL. Unaltered kinase
FT                                activity. Decreased kinase activity; when
FT                                associated with F-463 and F-502.
FT   MUTAGEN     463    463       Y->E: Constitutive activation and
FT                                constitutive phosphorylation of S-738 and
FT                                S-742.
FT   MUTAGEN     463    463       Y->F: Decreased phosphorylation level
FT                                when coexpressed with either SRC or ABL
FT                                in HeLa cells. Decreased kinase activity.
FT   MUTAGEN     502    502       Y->E: Loss of activation.
FT   MUTAGEN     502    502       Y->F: Decreased phosphorylation level
FT                                when coexpressed with SRC in HeLa cells.
FT                                Unchanged phosphorylation level when
FT                                coexpressed with ABL. Unaltered kinase
FT                                activity. Decreased kinase activity; when
FT                                associated with F-432 and F-502.
FT   MUTAGEN     612    612       K->W: Loss of kinase activity.
FT   CONFLICT    135    135       A -> R (in Ref. 1; CAA53384).
FT   CONFLICT    877    877       G -> R (in Ref. 1; CAA53384).
SQ   SEQUENCE   912 AA;  101704 MW;  0BC9414C335D2DBB CRC64;
     MSAPPVLRPP SPLLPVAAAA AAAAAALVPG SGPGPAPFLA PVAAPVGGIS FHLQIGLSRE
     PVLLLQDSSG DYSLAHVREM ACSIVDQKFP ECGFYGMYDK ILLFRHDPTS ENILQLVKAA
     SDIQEGDLIE VVLSASATFE DFQIRPHALF VHSYRAPAFC DHCGEMLWGL VRQGLKCEGC
     GLNYHKRCAF KIPNNCSGVR RRRLSNVSLT GVSTIRTSSA ELSTSAPDEP LLQKSPSESF
     IGREKRSNSQ SYIGRPIHLD KILMSKVKVP HTFVIHSYTR PTVCQYCKKL LKGLFRQGLQ
     CKDCRFNCHK RCAPKVPNNC LGEVTINGDL LSPGAESDVV MEEGSDDNDS ERNSGLMDDM
     EEAMVQDAEM AMAECQNDSG EMQDPDPDHE DANRTISPST SNNIPLMRVV QSVKHTKRKS
     STVMKEGWMV HYTSKDTLRK RHYWRLDSKC ITLFQNDTGS RYYKEIPLSE ILSLEPVKTS
     ALIPNGANPH CFEITTANVV YYVGENVVNP SSPSPNNSVL TSGVGADVAR MWEIAIQHAL
     MPVIPKGSSV GTGTNLHRDI SVSISVSNCQ IQENVDISTV YQIFPDEVLG SGQFGIVYGG
     KHRKTGRDVA IKIIDKLRFP TKQESQLRNE VAILQNLHHP GVVNLECMFE TPERVFVVME
     KLHGDMLEMI LSSEKGRLPE HITKFLITQI LVALRHLHFK NIVHCDLKPE NVLLASADPF
     PQVKLCDFGF ARIIGEKSFR RSVVGTPAYL APEVLRNKGY NRSLDMWSVG VIIYVSLSGT
     FPFNEDEDIH DQIQNAAFMY PPNPWKEISH EAIDLINNLL QVKMRKRYSV DKTLSHPWLQ
     DYQTWLDLRE LECKIGERYI THESDDLRWE KYAGEQGLQY PTHLINPSAS HSDTPETEET
     EMKALGERVS IL
//
